Allergan plc (NYSE: AGN), a Dublin, Ireland-based global pharmaceutical company, acquired Anterios, Inc., a New York, NY-based clinical stage biopharmaceutical company developing a delivery system and botulinum toxin-based prescription products.
Under the terms of the agreement, Allergan will make an upfront payment of $90m and potential development and commercialization milestone payments related to NDS™, Anterios’ proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.
In addition to NDS™, Allergan has acquired global rights to ANT-1207, an investigational topical formulation botulinum toxin type A in development for the potential treatment of hyperhidrosis (excessive sweating), acne, and crow’s feet lines.
The NDS™ platform technology and ANT-1207 add to Allergan’s neurotoxin pipeline, with BOTOX® Cosmetic (onabotulinumtoxinA) currently in development for treating forehead lines, masseter hypertrophy and platysma bands and BOTOX® Therapeutic in development for osteoarthritis and depression.
Prior to the closing, Anterios spun out certain assets to a new company, Eirion Therapeutics, Inc., funded by Anterios shareholders. The new entity also retains certain non-exclusive rights to ANT-1207.